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ABSTRACT
Background The rise in genomic and biobanking
research worldwide has led to the development of
different informed consent models for use in such
research. This study analyses consent documents used
by investigators in the H3Africa (Human Heredity and
Health in Africa) Consortium.
Methods A qualitative method for text analysis was
used to analyse consent documents used in the
collection of samples and data in H3Africa projects.
Thematic domains included type of consent model,
explanations of genetics/genomics, data sharing and
feedback of test results.
Results Informed consent documents for 13 of the
19 H3Africa projects were analysed. Seven projects used
broad consent, ﬁve projects used tiered consent and one
used speciﬁc consent. Genetics was mostly explained in
terms of inherited characteristics, heredity and health,
genes and disease causation, or disease susceptibility.
Only one project made provisions for the feedback of
individual genetic results.
Conclusion H3Africa research makes use of three
consent models—speciﬁc, tiered and broad consent.
We outlined different strategies used by H3Africa
investigators to explain concepts in genomics to
potential research participants. To further ensure that the
decision to participate in genomic research is informed
and meaningful, we recommend that innovative
approaches to the informed consent process be
developed, preferably in consultation with research
participants, research ethics committees and researchers
in Africa.
INTRODUCTION
The global interest in genomic and biobanking
research has led to an evolving understanding of
appropriate consent models for use in these types
of investigations.1 2 Consent models range from
speciﬁc consent for the collection and use of
human biological samples and data in a particular
project to broad and blanket consent for all future
uses, with several options in between.3–5 Tassé
et al3 identiﬁed the following consent models cur-
rently in use: (1) broad and blanket consent; (2)
tiered consent with different options for sharing
and secondary use; (3) presumed consent for
sharing; (4) recontacting or reconsenting for
sharing; (5) waived consent; and (6) no consent
(because no data with identiﬁers is used). In add-
ition, some projects are exploring possibilities for
dynamic consent, where research participants can
provide consent on an ongoing basis using social
media.6 7
Most analyses of consent forms used in biobank-
ing and genomic research8 9 have focused on
research taking place in Europe and North
America. While there is now a small literature on
consent for biobanking and genomics research in
resource-limited locations, including African set-
tings,10–16 many questions remain. For example,
there are few data on the use of broad consent for
health research in Africa including how key con-
cepts in genetic and genomic research such as data
and sample sharing, biobanking and reuse of
samples collected as part of research are explained
to research participants.
The Human Heredity and Health in Africa
(H3Africa) Consortium is a collection of research
and infrastructure projects seeking to apply genom-
ics methodology to diseases affecting African
people.17 Currently, H3Africa involves 26 funded
projects: 15 genomics research projects, 4 biobank-
ing projects, 6 Ethical, Legal and Social
Implications projects and a pan-African bioinfor-
matics network, H3ABioNet. Most of the genomics
research projects involve several research sites
across Africa. In 2014, the H3Africa Consortium
developed guidelines for informed consent, which
also contain template text for use in the develop-
ment of project-speciﬁc consent documents (http://
www.h3africa.org). These guidelines are not pre-
scriptive and H3Africa researchers determine the
most appropriate consent model considering the
needs of their study population as well as their
country-speciﬁc ethical and legal norms.
The development of H3Africa has prompted
African researchers to grapple with the complex-
ities around informed consent for genomics and
biobanking research. The purpose of this paper is:
(1) to describe how complex concepts in genomics
are explained in consent documents used by
H3Africa investigators; and (2) to explore consent
models that are currently used in H3Africa
projects.
METHODS
We sourced informed consent documents used in
H3Africa projects. We contacted principal investi-
gators (PIs) of the 15 genomics projects and the 4
biobanking projects. PIs were contacted via email
and asked for copies of informed consent
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documents and supporting materials used for participant
recruitment in their H3Africa projects. Documents were
imported into NVivo V.10 software18 and coded. Where
consent documents for different research sites differed substan-
tially, we coded each source separately. Where there were minor
variations in the names of places and people, we coded only
one of the documents.
Two researchers (NSM and JdV) conducted the data analysis.
Initial coding was performed to identify thematic domains.19
This was followed by a systematic review of these domains to
ensure content validity. A coding scheme was developed which
included the following items: (1) consent model (2) explana-
tions of genetics/genomics; (3) explanations of data and sample
sharing; (4) feedback of results and (5) H3Africa policies.20 21
The application of codes was discussed and when necessary,
content was recoded. Both researchers could read English and
French allowing for all forms to be analysed in the original
language. Some of these consent forms had been translated into
other languages (Xhosa, Afrikaans, Swahili, Amaharic,
Chichiwa, Chitumbuka and Luganda) but we did not include
any of these translated versions in the current analysis. The
initial project idea, preliminary ﬁndings and drafts of the manu-
script were presented to and discussed with members of the
H3Africa Working Group on Ethics and Regulatory Issues.
RESULTS
Of the 19 H3Africa genomics research studies and biobanking
projects currently taking place, we received documents for 13
projects (12 research projects and 1 biobanking project). Most
of the projects for which we received forms were enrolling par-
ticipants in multiple sites, often across different African coun-
tries. One of these projects did not involve the collection of
human biological samples per se, but of parasite samples from
the human body. Three PIs informed us that they were not col-
lecting (human) samples in their project. We did not receive a
response from three other PIs. Together, the projects for which
we analysed documents were engaged in sample collection in 22
countries across multiple sites. Most projects used the same
consent documents in all sites, with minor variations in the
names of places or people involved in enrolment. Only one
project used documents that differed across study sites, with
regards to the data and sample sharing descriptions. In total, 41
consent documents were collected. Of these, 3 were in French
and 38 in English.
The length of the information sheets ranged from 2 to 11
pages, with an average length of 6.5 pages. Four projects had
separate information sheets for different aspects of the study.
For example, one project separated information about the main
trait association study from information about the population
genomic study, while another project separated information
about sample sharing from the main study description. Where
this was the case, we grouped the various information sheets
together and analysed all information shared with participants.
Consent models used by H3Africa projects
Of the 13 projects, 5 used a tiered consent model, 7 used a
broad consent model and 1 used a speciﬁc consent model. One
group began with a tiered consent model but moved to a broad
consent model for pragmatic reasons. The project focusing on
pathogen genomics did not mention data or sample sharing and
only gave the option of consenting to be part of the study (spe-
ciﬁc consent). Of the four projects using tiered consent, two
offered participants a choice between either sample destruction
or depositing of samples in a biobank. The other two projects
offered an additional choice between sharing for research in a
disease-related ﬁeld, or for ‘all’ future research.
Explanation of genetics/genomics
We identiﬁed ﬁve strategies used by researchers to explain genet-
ics and genomics to research participants. Explanations focused
on heredity, heredity and health, genes and disease causation,
disease susceptibility and progression, and heredity and pheno-
type (see table 1). Most of the 13 projects used a blend of these
ﬁve different strategies at different locations in the consent
Table 1 Strategies for explaining genetics/genomics in consent documents used in H3Africa studies
Defining genetics/ genomics Common examples taken from the consent documents
Heredity (7 projects) DNA is the code that you inherit from your parents and that you pass on to your children.
This information may also be passed on from parent to child.
This kind of information is passed from the father and the mother to their children and on to their grandchildren, in other words,
from one generation to the next.
Heredity and health (3 projects) Some illnesses are passed down in families because our DNA comes from our parents.
To understand how inherited differences (traits that we get from our parents) influence our health.
If an inherited change gives the person a health advantage, then people with that change will be more likely to survive and pass
the change on to their children.
Genes and disease causation
(5 projects)
Also, some, but not all, sicknesses can be caused by problems with DNA.
Studying genes along with health information will help the researchers better understand what causes certain diseases.
Aider à trouver le « gène » précis à l’origine du trouble médical dans votre famille (translation: Help to find the precise ‘gene’
that lies at the origin of the medical issues in your family’).
We compare the DNA of the two groups so that we can see if there is any problem with the DNA causing the sicknesses.
Disease susceptibility and progression
(3 projects)
To discover new genes, or new patterns in the way genes are used, that may help understand reasons for how quickly disease X
progresses.
Examine genes in people with disease X to help understand why some people develop their diseases faster than others.
Some of these genes may prevent us from getting sick in the first place. Some other genes may be one of the reasons we get sick
when others do not.
Comment les changements au niveau du gène peuvent être responsables de vos symptômes (translation: How gene-level changes
could be responsible for your symptoms).
Heredity and phenotype (physical traits)
(4 projects)
These ‘genes’ are present in all of us and are what make people in families look like each other, but different from others. For
example, some families are taller or shorter than others.
The genetic material helps to decide for instance how tall you will be, what your body shape will be.
This kind of information is passed from parents to children (which is why family members often look like each other).
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documents, with 5 out of 13 blending two of these strategies.
Two projects used one strategy, while three projects drew on
three or more strategies. One project did not explain much
about genetics but focused on explaining the disease under
investigation.
The most common strategy used to explain genetics/genomics
was by pointing to family inheritance, or the way that particular
‘information’ is passed from parents to children (Row 1 in
table 1). Seven projects used this strategy. Of these, three pro-
jects linked this explanation to a discussion of diseases and how
they are often passed on between family members (Row 2 in
table 1). A further two projects started their explanation of
genetics with the passing on of diseases in families. Four
projects also linked such explanations to observations of how
physical traits (height, body shape) are inherited in families
(Row 5 in table 1).
Three projects linked their explanation of genetics and gen-
omics to disease susceptibility and progression by highlighting
the role of genes in inﬂuencing how quickly someone may
become ill with a particular disease, or how they may respond
to treatment (Row 4 in table 1). Three projects used a more ‘sci-
entiﬁc’ explanation in deﬁning genes. For example, genes were
deﬁned as ‘molecular units of heredity’ that ‘hold information
about how our bodies work’ or that ‘carry the instructions for
your body’s development and function’. These three projects
did not explain genetics any further.
With regards to the source of genomic material, some projects
simply referred to ‘blood’ whereas others explained that the
genetic material can be found in all cells in the body or in body
tissues. Others did not specify a location of the genetic material
but simply talked about ‘the genetic material in the body’.
Explanation of data and sample sharing
All but one of the consent forms that we reviewed included a
statement about data sharing. Ten out of 13 included a descrip-
tion of what sample sharing entailed. Of the three projects that
did not include this description, two did not anticipate the need
for sample sharing, while the third project collected only patho-
gen samples (taken from human samples). Of the projects that
sought consent for sample and data sharing, most blended their
descriptions of sample and data sharing into one.
In examining the forms, we identiﬁed four key elements asso-
ciated with explanations of data and sample sharing: authorities
deciding on reuse of samples, restrictions on secondary use,
reasons for storing and deﬁnitions of biobanks (see table 2).
Three projects speciﬁed that requests for secondary use would
be reviewed by the ethics committees that approved the original
study and one project speciﬁed that this task would fall to the
Ministry of Health in the country where samples were collected.
One project indicated that the funding agency would review
requests for secondary use of samples, while four other projects
indicated that this would be done by a special committee, a
group of researchers or the biobank.
Five of the 13 projects mentioned a timeline for sample
storage noting that samples would be stored either indeﬁnitely
(2 projects), for the study duration (1 project) or for 15 years
(2 projects). However, the majority of projects (8) did not
mention the length of storage. With regards to describing who
may use the data, most forms were rather broad, indicating that
‘other researchers around the world’ could use the data for
‘other projects’. Two projects restricted the utility of the data to
a particular disease or disease group, while four projects indi-
cated that samples and data would only be used for ‘scientiﬁc
Table 2 Qualitative content analysis on different ways of explaining data and sample sharing
Data or sample
sharing aspect Description Common examples taken from the consent documents
Authority deciding on
reuse of samples
Research ethics committees that approved original
study (4 projects)
These samples and related information may be used for other research studies in
our country or abroad, pending ethical approval by our ethics committee
Special committee, group of investigators or more
broadly ‘permission from the biobank’ (4 projects)
A special committee will look at each request to study samples to find out what the
researchers want to do and how they will protect your rights.
Funding agency (1 project) The control over samples you donate will be held by the funding agency.
Ministry of Health (1 collaborating site in a project) L’accès et l’utilisation de ces échantillons ne pourront se faire sans l’accord du Ministère de
la Santé de notre pays (translation: Access and use of samples will have to be approved by
the Ministry of Health)
Restrictions on
secondary use
Only for ‘scientific’ or ‘medical’ research (5 projects) Although the study you are being asked to participate in is related to (Disease X), other
scientists may like to use your sample to study other diseases.
They will need to agree only to use the data for scientific research.
No restrictions (7 projects) Investigators from all over the world can use these samples for their research; samples may
be used to study other diseases.
Specific diseases (1 project and 1 collaborating site
in a project)
les échantillons vont être conservés en attendant leur utilisation par les chercheurs et
projets de recherches associés à notre projet
(translation: (the samples) will be stored for reuse by researchers and projects associated
with our project)
Reasons for storing To boost the power of studies and research
(2 projects)
To do more powerful research, it is helpful for researchers to share information they get
from studying human samples
Because this is now best practice (4 projects) It is now common that genetic information is shared with researchers around the world, for
other research in the future
Because it is the right thing to do (2 projects) A goal of H3Africa is to create a way for investigators to share and learn from each other,
especially within Africa. One of the best ways to do this is for scientists to share research
information
Definitions of Biobanks (7 projects) The storage place also known as a biorepository is a collection of samples and health
information from many people, stored for study.
A sophisticated blood storage facility.
Some of the samples may be stored as part of a big collection or ‘biobank’.‘A biobank is a
place that stores samples and information so that researchers on this study and other
scientists can use them in future unspecified research projects”
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research’ or ‘medical research’. Two projects detailed that
samples and data could be used by private sector investigators.
We examined reasons given for storing, which corresponds to
sharing samples and data across the projects and found that
while three projects gave no reason for sample sharing, ﬁve
main reasons were provided by the other projects. These
included: best practice (four projects), the right thing to do
(two projects), to facilitate future unspeciﬁed research (four pro-
jects), for the beneﬁt of science and medicine (one project), and
to boost the power of studies (two projects) (table 2).
In our assessment of how biobanks are explained in consent
forms, we found that seven projects offered some description of
what a biobank is, for instance that it is a ‘place where samples
are stored’. In terms of the location of the biobanks, eight pro-
jects stated that this will be ‘somewhere on the African contin-
ent’, two projects detailed the speciﬁc (African and non-African)
countries where samples will be stored, while three projects did
not mention a location.
Feedback of genetic and non-genetic results
In our analysis of feedback of study results, we separated genetic
study results from other test results. Nine projects indicated that
they would provide feedback on individual non-genetic test
results to research participants, while four projects did not
mention providing any feedback to participants. A variety of
non-genetic results were described in the consent forms, includ-
ing information about parasite density, blood pressure, blood
sugar and lipids, and results of echocardiograms.
Regarding feedback of individual-level genetic study results,
six projects did not mention whether they would return genetic
research results, while ﬁve projects speciﬁed that no genetic
research results would be returned. Reasons given for not
returning genetic results included that it could take a long time
before results would be known and that there is an incomplete
understanding of the role of genes in disease causation. Two
projects described the possibility that some results could be
shared in the future, using non-committal phrases like ‘there is a
small chance we may ﬁnd something important. If this happens,
we may contact you to ﬁnd out if you would like to learn
more’. One project indicated that participants could obtain the
results of the genetic tests at their request. This project provided
considerable detail about the types of ﬁndings that would be
given to participants. It distinguished treatable medical condi-
tions that have a clear genetic origin (which would be fed back),
from conditions for which genetic predisposition is only a con-
tributing factor (no feedback on these conditions would be pro-
vided to participants). All relevant ﬁndings would be veriﬁed in
a diagnostic facility and feedback would be given by a study
doctor and a genetic counsellor.
H3Africa policies
Six of the 13 projects did not refer to the H3Africa Consortium
in their consent forms. Of the other projects, most made
minimal mention, describing for instance that ‘this study is part
of the H3Africa project’, or ‘samples will be held in an
H3Africa biobank’ but without further details. None of the pro-
jects referred to the H3Africa policy framework, which is not
surprising as most projects developed their consent documents
before the policy framework was developed.
DISCUSSION
In this article, which comprises the ﬁrst comprehensive analysis
of consent documents and models used in the recruitment of
research participants for genomics and biobanking research in
Africa, we have documented how H3Africa researchers explain
key concepts of genomic research to study participants and the
type of consent models used in H3Africa projects.
There are ongoing discussions about the appropriateness of
using broad consent when recruiting research participants with
low health-literacy in resource-poor settings.22 23 Challenges
relating to the use of broad consent models in Africa are mul-
tiple and include questions about research participant compre-
hension of concepts in genomic research, future use of samples
collected as part of research and the possible risk of stigma or
exploitation of study communities.24 25 There is also a regula-
tory gap and limited legal and ethical guidance available in
Africa to support a transition from speciﬁc to broad consent
models.26–28 Taken together, these questions translate into con-
siderable apprehension by African research ethics committees to
approve research that makes use of broad consent. Despite these
concerns, our study shows that most H3Africa projects adopted
a broad consent model.
In H3Africa, broad consent for genomic and biobanking
studies is currently mandated by funding requirements. For gen-
omics research, the sharing of data for secondary use is now
standard practice, and a requirement imposed by most of the
large funding agencies.29 30 Similarly, biobanking is only mean-
ingful if samples are shared widely, and if consent is broad
enough to allow for wide reuse of samples. The introduction of
broad consent requirements in African health research may be
good—for instance, if broad consent cannot be used for the
recruitment of African research participants in genomics and
biobanking research, then it is possible that Africa will be
further excluded from genomics and biobanking research, thus
not remedying the existing underrepresentation of African
people in such research31 and preventing African populations
from harnessing the potential health beneﬁts of human genom-
ics research17 29—an outcome that would clearly be unjust.32
This is particularly true when there is emerging evidence from
Africa that research participants are supportive of broad consent
where this promotes health research and reduces global health
inequality.33 34
But at the same time, the requirement for broad consent in
H3Africa research raises questions about the way in which
ethical norms in Africa are formulated and evolve. Medical
research in Africa is closely associated with concerns of imperi-
alism and exploitation.35 36 The imposition of non-African
ethical standards on research in Africa has also long been a
concern in global health ethics.37 38 The real challenge at stake
is to ﬁnd a way to foster African deliberation on and adaptation
of ethical norms introduced by novel scientiﬁc practices,
without this process compromising potential beneﬁt of African
genomics research to patients. Within the context of H3Africa,
the approach has been to foster ethical deliberation32 while also
getting on with research—but whether this is indeed the best
approach to fostering ethical debate remains to be seen.
Informed consent is one important strategy to avoid potential
exploitation of research participants and protect their rights and
well-being39—but only if the consent process is designed in a
way that is culturally appropriate and understandable.
Investigators examining consent to genomic research in African
settings have identiﬁed a number of challenges in communicat-
ing study goals, methods and procedures.12–14 40 This is com-
pounded by difﬁculties in ﬁnding equivalent terminology to
explain pertinent concepts in local languages.12 In our examin-
ation of consent documents, we found that researchers sought
to ﬁnd layperson explanations of some of the difﬁcult concepts
in genomics. We demonstrated that there was diversity across
Munung NS, et al. J Med Ethics 2016;42:132–137. doi:10.1136/medethics-2015-102796 135
Research ethics
projects in the strategies used to explain key concepts of genom-
ics research. However, consistent across many documents was
reference to some notion of heredity, on its own or as linked to
phenotype, disease causation or progression as a means of
explaining genomics and genetics.
The need for sample and data sharing was explained by sug-
gesting that this represents scientiﬁc best practice, that it facili-
tates future research and that it would beneﬁt science and
medicine. In terms of secondary use of samples, many projects
suggested that this will be done by a local Research Ethics
Committee (REC) and/or a ‘special committee’. This reﬂects the
views of some African REC members that the reuse of samples
collected as part of research has to be monitored by African
RECs.22 23 25 The H3Africa policy framework however suggests
that a Data and Biospecimen Access Committee should decide
on sample and data access.32 This potential tension between the
content of H3A consent forms and the policy framework will
need to be addressed in the actual management of secondary
sample and data access. This observation raises larger questions
about the content of consent documents and how this is
respected down the line.
The absence of information about the feedback of individual
genetic study results in most forms—and a clear commitment to
return genetic results in only one project—illustrates the fact
that in Africa, there is little or no experience with or opportun-
ity for integrating genetic ﬁndings into personal healthcare, as
evidenced by the nearly complete absence of this topic in aca-
demic literature.41 The question of whether and how health
related ﬁndings in genomic research should and could be
returned to African research participants will require further
empirical work. Arguably, the feedback of study ﬁndings could
lead to an increase in the number of people that need to be fol-
lowed up in the healthcare system, which in many African coun-
tries are already overburdened and struggling to cope with
patients requiring acute care. The question is whether the add-
ition of patients who do not yet manifest disease is morally
acceptable.
One limitation of our analysis is that we focused on English
and French language consent documents, and did not include
the direct translations made into local African languages. We
also did not consider how local language versions of these
informed consent documents are used in practice. We did not
include translations for a number of reasons, most importantly
because of the immensity of the task involved. As we indicated,
the forms we analysed are used in multiple research sites across
22 countries, and each project may translate consent documents
into three or four languages. This would mean that we would
have had to deal with over 100 translations—the analysis of
which would have had to be done by people able to read the
languages involved. Although important, we also think that this
was outside of the scope of the project. However, it is of key
importance that our analysis be accompanied by studies examin-
ing the use of linguistic and conceptually equivalent terminology
in local African languages to explain pertinent concepts in gen-
omics, and by empirical studies examining the broader consent
processes, including participant comprehension.
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